fda tirzepatide weight loss says compounding pharmacies can keep making weight-loss med tirzepatide, for now Tirzepatide Wins FDA Approval for

During a 17-week off-treatment follow-up period, people who had stopped using tirzepatide began to regain weight, Lilly said in a news release, and there was some increase in the progression to type 2 diabetes. The most frequently reported adverse events were typically gastrointestinal-related and generally mild to moderate in severity, Lilly said

But it will also complicate the future of compounded versions of the medications

Timeline comparison: when results appear The dosage chart dictates your schedule

Do not microwave it, run it under hot water, or place it near a heat source

Compounded medications are not FDA-approved and are only used when determined appropriate by the treating provider.

Both the pen and vial come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses